Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M S BARTLETT

Showing results (231-240 of 386) with videos related to

Pageof 39
Sort By:
Plos One|June 23, 2017
Reliability and performance of commercial RNA and DNA extraction kits for FFPE tissue coresPalak G Patel, Shamini Selvarajah, Karl-Philippe Guérard, et al.
Breast Cancer Research and Treatment|September 15, 2012
GSK3β and cyclin D1 expression predicts outcome in early breast cancer patientsMary Anne Quintayo, Alison F Munro, Jeremy Thomas, et al.
Histopathology|May 26, 2006
Observer variation in immunohistochemical analysis of protein expression, time for a change?T Kirkegaard, J Edwards, S Tovey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2007
Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patientsTove Kirkegaard, Liane M McGlynn, Fiona M Campbell, et al.
American Journal of Clinical Pathology|December 20, 2008
External quality assurance of HER2 FISH and ISH testing: three years of the UK national external quality assurance schemeJohn M S Bartlett, Merdol Ibrahim, Bharat Jasani, et al.
Histopathology|April 9, 2008
Genetic alterations of CCND1 and EMSY in breast cancersT Kirkegaard, K V Nielsen, L B Jensen, et al.
American Journal of Clinical Pathology|December 22, 2010
A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assayJ M S Bartlett, Fiona M Campbell, Merdol Ibrahim, et al.
Breast Cancer Research and Treatment|March 22, 2017
Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II studyKonstantinos Tryfonidis, S Marreaud, H Khaled, et al.
Breast Cancer Research and Treatment|June 4, 2011
In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancerMelanie Spears, Karen J Taylor, Alison F Munro, et al.
Oncotarget|September 16, 2015
A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trialsMelanie Spears, Fouad Yousif, Nicola Lyttle, et al.
Pageof 39

Showing results (231-240 of 386) with videos related to

Sort By:
Pageof 39
Plos One|June 23, 2017
Reliability and performance of commercial RNA and DNA extraction kits for FFPE tissue coresPalak G Patel, Shamini Selvarajah, Karl-Philippe Guérard, et al.
Breast Cancer Research and Treatment|September 15, 2012
GSK3β and cyclin D1 expression predicts outcome in early breast cancer patientsMary Anne Quintayo, Alison F Munro, Jeremy Thomas, et al.
Histopathology|May 26, 2006
Observer variation in immunohistochemical analysis of protein expression, time for a change?T Kirkegaard, J Edwards, S Tovey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2007
Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patientsTove Kirkegaard, Liane M McGlynn, Fiona M Campbell, et al.
American Journal of Clinical Pathology|December 20, 2008
External quality assurance of HER2 FISH and ISH testing: three years of the UK national external quality assurance schemeJohn M S Bartlett, Merdol Ibrahim, Bharat Jasani, et al.
Histopathology|April 9, 2008
Genetic alterations of CCND1 and EMSY in breast cancersT Kirkegaard, K V Nielsen, L B Jensen, et al.
American Journal of Clinical Pathology|December 22, 2010
A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assayJ M S Bartlett, Fiona M Campbell, Merdol Ibrahim, et al.
Breast Cancer Research and Treatment|March 22, 2017
Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II studyKonstantinos Tryfonidis, S Marreaud, H Khaled, et al.
Breast Cancer Research and Treatment|June 4, 2011
In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancerMelanie Spears, Karen J Taylor, Alison F Munro, et al.
Oncotarget|September 16, 2015
A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trialsMelanie Spears, Fouad Yousif, Nicola Lyttle, et al.
Pageof 39